Search
for
Sort by
Research
300-330 / 1000+ results
research Ultrasound-Assisted Facile Synthesis and Anticancer Evaluation of Novel N-(2-substituted phenyl-4-oxathiazolidine-3-carbonothioyl) benzamide
Researchers made new compounds that could potentially be developed into anticancer drugs.
research Synthesis, Anticancer and Molecular Docking Studies of 2-(4-chlorophenyl)-5-aryl-1,3,4-Oxadiazole Analogues
The compound 4c showed strong potential as an anticancer agent.
research Small cell lung cancer: Results of a phase II study of 1,2,4 triglycidylurazol
The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
research Número Actual: Vol. 2 Núm. 4 (2021) Pág. 1-67
Laparoscopic cholecystectomy has aesthetic benefits, and maskne became common during COVID-19.
research 28th Turkish National Dermatology Congress, September 24–28, 2019, Antalya, Turkey
The congress was praised for its organization and educational value.
research Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24‐week randomized, double‐blind, placebo‐controlled clinical trial
Using antioxidants on the scalp can make it healthier and decrease hair loss.
research Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24‐Week Outcomes From a Prospective Real‐World Cohort
Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
research Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
research Faculty Opinions recommendation of Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial.
Low-level light therapy significantly increased hair density and thickness in people with hair loss, but they didn't notice a difference.
![Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)](/images/research/d743d32f-3115-48ff-9697-2f2d56130701/small/14175.jpg)
research Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)
The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
research Hair Growth-Promoting Effects of a Multi-Targeted Cosmetic Formulation Containing PYGL, DP2, and 15-PGDH Inhibitors Developed Using AI-Based DeepZema® in Androgenetic Alopecia: A 24-Week Randomized Controlled Trial
The formulation significantly increased hair density and thickness safely in people with androgenetic alopecia.
research 1. 2年間の低負荷レジスタンストレーニングが高齢者の筋機能に及ぼす効果(第134回日本体力医学会関東地方会)
Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.
![Discovery of (2S)-N-(6-Cyano-5-(Trifluoromethyl)Pyridin-3-Yl)-3-(6-(4-Cyanophenyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)-2-Hydroxy-2-Methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment](/images/research/693e7bf6-2325-4ddc-a20f-3470db9f4516/small/25627.jpg)
research Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment
A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research A Novel Approach Against Male Pattern Hair Loss With Topical Dimethylglycine Sodium Salt (DMG ‐Na) and Caffeine: Efficacy of a 24‐Week, Double‐Blind, Randomized, Placebo‐Controlled Trial
The shampoo with DMG-Na and caffeine effectively reduces hair loss and improves hair density in men.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
research Alterations in the Hair Follicle Bacteriome and Mycobiome in Androgenetic Alopecia: A Cross-Sectional Study of 72 Patients and 24 Healthy Controls
Androgenetic alopecia involves a fungal imbalance in hair follicles, suggesting potential for microbiome-targeted treatments.
research 61720 The effect of sublingual minoxidil on androgenetic alopecia in transgender individuals receiving testosterone for gender-affirmation: A 24-week single-centre double-blinded, randomized, placebo-controlled clinical trial
Sublingual minoxidil significantly improves hair growth in transgender individuals on testosterone therapy.
research Highlights from the Basics in Hair Restoration Course Afternoon Hands-On Stations Wednesday, August 24, 2005
research European Society of Hair Restoration Surgery: 10th Annual Congress & Live Surgery Workshop, Paris, France • May 24–27, 2007
research Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
research 15thJornada de DermatologÃa of the Faculty of Medicine, ClÃnica Alemana â University of Desarrollo, Santiago, Chile, October 22-24, 2009
The 15th Jornada de Dermatología was a successful dermatology event with international experts discussing various topics.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research Electron microscopy in dermatology--basic and clinical research : proceedings of the Joint Meeting for the Japanese Society for Ultrastructural Cutaneous Biology and the Society for Cutaneous Ultrastructure Research, Nara, Japan, 24-27 October 1993
Electron microscopy helps understand skin structure and diseases.
research Type 2 Cytokine–Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study
AD-derived keratinocytes effectively mimic inflammation in atopic dermatitis.
research 139 Anti-BCC efficacy of a topical hedgehog inhibitor without adverse effects in BCNS patients in a phase 2 randomized controlled trial
Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
research Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
Type-2 immunity may influence skin diseases and could be targeted for treatment.
research 1617 Impact of type 2 cytokines on the keratinocytes-s. aureus interaction
Type 2 cytokines IL-4 and IL-13 increase skin's vulnerability to Staphylococcus aureus, which could be important for treating atopic dermatitis.